← Back to headlines
Fulcrum Therapeutics Reports Q1 GAAP EPS of -$0.25, Beats Estimates
Fulcrum Therapeutics announced its GAAP EPS for the first quarter, reporting -$0.25 per share. This figure surpassed analyst expectations by $0.05.
27 Apr, 11:05 — 27 Apr, 11:05
Sources
Showing 1 of 1 sources
